• 1. The cooperative effect of Lewis pairs in the Friedel–Crafts hydroxyalkylation reaction: a simple and effective route for the synthesis of (±)-carbinoxamine
  Adhikesavan Harikrishnan,Jayakumar Sanjeevi,Chinnasamy Ramaraj Ramanathan Org. Biomol. Chem. 2015 13 3633
• 2. A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters
  Petar O. Nikiforov,Sachin Surade,Michal Blaszczyk,Vincent Delorme,Priscille Brodin,Alain R. Baulard,Tom L. Blundell,Chris Abell Org. Biomol. Chem. 2016 14 2318

Recent Advances in the Study of 3-(Piperidin-1-yl)aniline (CAS: 27969-75-1) in Chemical Biology and Pharmaceutical Research

3-(Piperidin-1-yl)aniline (CAS: 27969-75-1) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This aromatic amine derivative, featuring a piperidine moiety, has been increasingly studied for its potential applications in drug discovery and development. Recent studies have highlighted its role as a versatile scaffold for the synthesis of bioactive molecules, particularly in the context of central nervous system (CNS) disorders, cancer therapeutics, and antimicrobial agents.

One of the key areas of research involving 3-(Piperidin-1-yl)aniline is its application in the design of novel kinase inhibitors. Kinases are critical targets in cancer therapy, and the piperidine-aniline structure has been shown to enhance binding affinity and selectivity for specific kinase domains. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of 3-(Piperidin-1-yl)aniline exhibited potent inhibitory activity against EGFR (epidermal growth factor receptor) mutants, which are often implicated in non-small cell lung cancer (NSCLC). The study reported IC50 values in the nanomolar range, suggesting promising therapeutic potential.

In addition to its role in oncology, 3-(Piperidin-1-yl)aniline has been explored for its neuropharmacological properties. Research published in Bioorganic & Medicinal Chemistry Letters (2024) revealed that this compound serves as a precursor for the synthesis of serotonin receptor modulators. These modulators have shown efficacy in preclinical models of depression and anxiety, with improved blood-brain barrier permeability compared to existing therapeutics. The study emphasized the compound's ability to fine-tune receptor selectivity, reducing off-target effects.

Another notable application of 3-(Piperidin-1-yl)aniline is in the development of antimicrobial agents. A recent study in European Journal of Medicinal Chemistry (2024) synthesized a series of derivatives targeting bacterial efflux pumps, a major mechanism of antibiotic resistance. The results indicated that certain derivatives exhibited broad-spectrum activity against multidrug-resistant strains of Staphylococcus aureus and Escherichia coli. The researchers attributed this activity to the compound's ability to disrupt membrane integrity and inhibit efflux pump function.

The synthetic versatility of 3-(Piperidin-1-yl)aniline has also been leveraged in material science. A 2023 study in ACS Applied Materials & Interfaces reported its use as a building block for functionalized polymers with applications in drug delivery systems. The amine group facilitated covalent conjugation with polymeric carriers, enabling controlled release of encapsulated therapeutics. This approach has been particularly valuable for targeted delivery in cancer treatment, minimizing systemic toxicity.

Despite these advancements, challenges remain in the optimization of 3-(Piperidin-1-yl)aniline-based compounds. Issues such as metabolic stability, solubility, and potential off-target interactions require further investigation. Ongoing research is focusing on structural modifications to address these limitations, including the introduction of heterocyclic rings and polar substituents. Computational modeling and high-throughput screening are being employed to accelerate the discovery of optimized derivatives.

In conclusion, 3-(Piperidin-1-yl)aniline (CAS: 27969-75-1) continues to be a molecule of high interest in chemical biology and pharmaceutical research. Its diverse applications—from kinase inhibition to antimicrobial activity—highlight its potential as a multifunctional scaffold. Future studies are expected to explore its utility in additional therapeutic areas, such as immunomodulation and neurodegenerative diseases, further solidifying its role in modern drug discovery.

• 2359-60-6(4-(piperidin-1-yl)aniline)
• 16857-95-7(Piperidine, 1,1',1''-(1,3,5-benzenetriyl)tris-)
• 138226-65-0(Benzenamine, N-ethyl-4-(1-piperidinyl)-, hydrochloride (1:2))
• 27594-19-0(Piperidine, 1,1'-(1,3-phenylene)bis-)
• 138227-66-4(Benzenamine, 3-(1-piperidinyl)-, dihydrochloride)
• 138227-50-6(Benzenamine, N-butyl-4-(1-piperidinyl)-, hydrochloride (1:2))
• 138227-54-0(Benzenamine, N-hexadecyl-4-(1-piperidinyl)-, hydrochloride (1:2))
• 110475-33-7(4-Piperidinoaniline Hydrochloride)
• 4096-20-2(1-Phenyl-piperidine)
• 138227-52-8(Benzenamine, N-hexyl-4-(1-piperidinyl)-, dihydrochloride)